Combination treatment with radiotherapy and a novel oxidative phosphorylation inhibitor overcomes PD-1 resistance and enhances antitumor immunity

BACKGROUND: Despite outstanding responses to anti-PD-1 agents in a subset of non-small cell lung cancer (NSCLC) patients, approximately 80% of patients fail to have prolonged favorable response. Recent studies show that tumor cell oxidative metabolism is a barrier to PD-1 immunotherapy and radiother...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Dawei, Barsoumian, Hampartsoum B, Fischer, Grant, Yang, Liangpeng, Verma, Vivek, Younes, Ahmed I, Hu, Yun, Masropour, Fatemeh, Klein, Katherine, Vellano, Christopher, Marszalek, Joseph, Davies, Michael, Cortez, Maria Angelica, Welsh, James
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7319777/
https://www.ncbi.nlm.nih.gov/pubmed/32581056
http://dx.doi.org/10.1136/jitc-2019-000289

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7319777/
https://www.ncbi.nlm.nih.gov/pubmed/32581056
http://dx.doi.org/10.1136/jitc-2019-000289

Ejemplares similares